HARVARD BIOSCIENCE INC

HBIO represents Harvard Bioscience, a company that develops and sells scientific instruments, lab equipment, and related technologies used primarily in life science research. Its products support areas such as physiology, cell biology, and drug discovery. HBIO serves pharmaceutical companies, academic institutions, and government labs worldwide, generating revenue through product sales and services tied to the research and healthcare markets.

The latest price for HBIO shares is shown in real time at the top of this stock detail page. Because quotes update throughout the trading day, any figure here would only reflect a moment in time. For the most accurate and current HBIO price, including pre-market or after-hours movement, check the live quote and timestamp displayed on the page.

Whether HBIO trades above or below its intrinsic value depends on current market data and valuation metrics that change frequently. This page does not provide a fixed fair-value estimate. To judge HBIO's valuation, review the live figures shown here, such as price-to-sales or price-to-earnings ratios, and compare them with sector peers and the company's own historical averages.

HBIO can be purchased through a brokerage account that offers access to U.S. exchanges. Investors typically open or log into an account, search for the ticker HBIO, and place a market or limit order during regular trading hours. Fractional shares may be available at some brokers. Availability and fees vary by platform, so confirm your broker's specific HBIO trading terms.

HBIO has not historically paid regular cash dividends, so income-focused investors should not expect a dividend stream from this stock. If HBIO's board were to initiate or change a dividend policy, the company would disclose it through official filings. For the latest dividend status, check HBIO's most recent quarterly reports or investor relations announcements.

Key risks for HBIO include dependence on research and academic spending, which can fluctuate with government budgets and grant funding. As a smaller-cap company, HBIO may also face limited financial resources, competition from larger instrument makers, and exposure to foreign currency and supply-chain disruptions. Changes in healthcare or science policy could further affect demand for its products and services.